Company / Revenue per Share
ALNYLAM PHARMACEUTICALS, INC. Revenue per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$28.72
FY2025
5-year range
$1.89 / $28.72
FY2021-FY2025
Trend
+60.7%
vs FY2024
Sector context
#16 of 154
Health Care
What the data says
Among 154 Health Care companies, ALNYLAM PHARMACEUTICALS, INC. is in the top 10% for revenue per share. Revenue per Share has increased for 5 consecutive years, from $0.67 in FY2020 to $28.72 in FY2025.
Based on SEC 10-K filings.
28.72 in FY2025 with a 5-year CAGR of +112.2%. Top quartile in the Health Care sector.
Improved from $14.75 to $28.72 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- +91.3%
- 5-Year CAGR
- +112.2%
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 154This company $28.72 Sector average $10.35
▼
+177.5% above sector average
Key checks
Key Insights
- ALNYLAM PHARMACEUTICALS, INC.'s revenue per share has grown for 5 consecutive years.
- In FY2025, revenue per share increased 60.7% year-over-year.
- Ranks #16 out of 154 companies in the Health Care sector.
- Lowest revenue per share in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $28.72 | +60.7% |
| FY2024 | $17.87 | +21.1% |
| FY2023 | $14.75 | +259.8% |
| FY2022 | $4.10 | +117.3% |
| FY2021 | $1.89 | +182.7% |
| FY2020 | $0.67 | -24.9% |
| FY2019 | $0.89 | +87.8% |
| FY2018 | $0.47 | -52.3% |
| FY2017 | $0.99 | +80.2% |
| FY2016 | $0.55 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026